Becton Dickinson: Alaris overhang masks a clean path to $10 EPS by FY2029

Stevie AI on Becton, Dickinson and Company (BDX-USA | bectondickin)

10/26/2026

Summary

Becton Dickinson is a diversified medtech franchise spanning blood collection and vascular access (Medical Essentials), infusion pumps and patient monitoring (Connected Care), and peripheral vascular/urology/oncology devices (Interventional). The company's core insight is simple: BD sells consumables and capital equipment into entrenched, multi-year hospital sourcing agreements, giving it recurring, sticky revenue that is currently being undervalued because the market is fixated on a transitory Alaris infusion pump remediation headwind rather than the underlying earnings trajectory. The stock trades at roughly 33x FY2025 EPS of $5.83, a multiple that looks rich on trailing numbers but cheap once FY2027-2029 EPS acceleration is modeled through. FY2024 revenue of $20.2B grew to $21.8B in FY2025, though net income was roughly flat at $1.7B both years as margin pressure from tariffs, Alaris remediation costs, and input cost inflation offset BD Excellence productivity gains, compressing EPS slightly from $5.86 to $5.83. FY2026 guidance calls for a reacceleration to ~4.5% revenue growth (aided by FX) and EPS of $6.24, followed by a deceleration to 2.5% growth in FY2027 as the Alaris headwind peaks at 200bps, before margin expansion and innovation-driven mix shift push EPS to $7.41, $8.72, and $10.08 in FY2027-FY2029 respectively. Applying an 18x forward P/E to FY2029E EPS of $10.08 — a modest premium to the medtech peer group reflecting BD's improving FCF conversion and de-levering balance sheet, but below best-in-class peers given BD's lower organic growth and ongoing remediation risk — yields a FY2029 price target of approximately $181.44, which discounted back at 10% annually gives $150.16 for FY2026 (first positive-EPS year used as anchor is actually FY2026 itself, so the FY2026-2028 targets are built forward from the FY2029 anchor). This implies the current $195.53 price already reflects the back half of our forecast period, but the EPS compounding (6.24 to 10.08, a 62% increase over three years) suggests the stock can work from current levels as execution derisks the Alaris overhang and FY2027 formal guidance in November provides a positive catalyst.

Thesis

**1. Entrenched Market Position in Mature but Essential Categories** BD holds top-2/3 share in blood collection, infusion therapy, patient monitoring, and peripheral vascular intervention — categories that are unglamorous but structurally resistant to disruption because hospital procurement cycles are long, clinical switching costs are high, and BD bundles capital equipment (Alaris pumps, HemoSphere monitors) with disposables and service contracts. This creates multi-year revenue visibility that the market underappreciates when it fixates on quarter-to-quarter growth deceleration. The Rule Breaker score of 4.45/10 and Blue Ocean score of 6.0/10 confirm BD is not a disruptive innovator but rather a share-defender in contested spaces, with selective moves into uncontested niches like device-drug combination products. This is not a criticism — it is the correct strategic posture for a company with BD's scale and distribution advantages, and it supports durable, if unspectacular, double-digit-to-teens EPS growth once remediation costs roll off. **2. Margin Expansion Story Is Underwritten by BD Excellence, Not Hope** The forecast shows net income nearly doubling from $1.7B in FY2025 to $2.7B in FY2029 on revenue growth of only ~16% cumulatively ($21.8B to $25.2B), implying substantial net margin expansion from 7.7% to roughly 10.7%. This is driven by the BD Excellence productivity program and favorable mix shift toward higher-margin device-drug combination products, not aggressive revenue assumptions — a lower-risk way to compound earnings. Management's FY2026 adjusted operating margin guidance of ~25%, held steady even with tariff headwinds, signals the productivity program is delivering real offsets. The deceleration in FY2027 is a known, quantified headwind (200bps from Alaris) rather than an open-ended risk, which should allow the market to price it in cleanly once November guidance arrives. **3. EPS Inflection From FY2026 to FY2029 Is the Core of the Mispricing** EPS of $6.24 in FY2026 rising to $10.08 by FY2029 represents a 62% cumulative increase, or roughly a 17% CAGR, well above the single-digit revenue growth underlying it. The market, trading BD at a trailing-ish multiple reflecting FY2025's flat EPS year, has not yet re-rated for this acceleration curve, in part because the near-term FY2027 deceleration obscures the longer-dated trajectory. This is a classic sum-of-the-parts timing mismatch: investors see the FY2027 air pocket and extrapolate caution, missing that FY2028-2029 EPS growth (18% and 16% respectively) more than compensates. As formal FY2027 guidance is issued in November and the Alaris remediation timeline becomes more concrete, we expect multiple expansion toward peer averages. **4. Capital Allocation Supports the Equity Story Independent of Revenue Surprises** Free cash flow grows from $2.9B in FY2026 to $3.5B in FY2029 while net debt stays essentially flat around $18.3-18.4B, meaning net leverage is quietly declining as EBITDA grows. This funds continued share buybacks and the stated move toward a 90% FCF conversion target, both of which are EPS-accretive levers independent of top-line execution risk. Dividend growth, historically 8-10% annually and expected to moderate but continue, adds a total-return floor. For a stock yielding a modest but growing dividend alongside consistent buybacks, this is a lower-volatility way to participate in the EPS re-rating thesis. **5. Catalysts Are Concrete and Dated** The November 2026 earnings call will deliver formal FY2027 guidance, providing the first hard data point on how much of the 200bps Alaris headwind is already priced into consensus versus how much remains a surprise risk. A separate Investor Day will lay out long-term strategic targets and pipeline details, which should help the market model the FY2028-2029 reacceleration with more confidence. Both events function as de-risking catalysts: if management demonstrates the

Risks

**1. Alaris Remediation Timeline and Litigation Exposure** The Alaris infusion pump remediation is the single largest overhang on the stock. The headwind escalates from 100bps in FY2026 Q3 to 200bps in Q4 and persists into FY2027, and the company faces 2,380 pending product liability loss contingency claims with only a $98M accrual against them. If remediation costs or settlement amounts exceed current reserves, or if the regulatory resolution timeline extends beyond FY2027, the modeled EPS reacceleration in FY2028-2029 could be delayed or reduced, directly undermining the long-duration thesis this report is built on. **2. Tariff and Input Cost Pressure Could Prove Stickier Than Modeled** The forecast assumes BD Excellence productivity gains offset tariff costs and elevated energy/commodity price pressure (WTI 80-100 band) to hold adjusted operating margin near 25% in FY2026. If tariffs escalate further or commodity costs spike above the assumed range, margin expansion could stall, compressing the EPS growth path that underpins the valuation re-rating case. Medtech companies have limited near-term pricing power against hospital systems, making cost pass-through difficult. **3. China Market Volatility** China exposure introduces both demand volatility (VBP procurement reform, anti-corruption campaigns affecting hospital purchasing) and currency/regulatory risk that is not fully detailed in the provided guidance but is flagged as a standalone risk factor. Any sharp deterioration in China hospital capital equipment spending would disproportionately affect the Connected Care and Interventional segments. **4. FY2027 Guidance Could Disappoint Relative to

📈 Price Targets